Prevention Surpasses Treatment: 5-year Follow-Up, Cost-Utility, and Cost–Benefit of Zeaxanthin Therapy for Neovascular Age-Related Macular Degeneration-Reference-Cited by-同舟云学术

Prevention Surpasses Treatment: 5-year Follow-Up, Cost-Utility, and Cost–Benefit of Zeaxanthin Therapy for Neovascular Age-Related Macular Degeneration

Published:2023-07-10 Issue:5 Volume:12 Page:2583-2608
ISSN:2193-8245
Container-title:Ophthalmology and Therapy
language:en
Short-container-title:Ophthalmol Ther

Author:

Brown Gary C.^ORCID,Brown Melissa M.,Gierhart Dennis,Olk R. Joseph

Funder

Performance of the study, manuscript preparation, and the open access fee were supported in part by a grant from ZeaVision, Inc., Chesterfield, MO.

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology

Link

https://link.springer.com/content/pdf/10.1007/s40123-023-00742-9.pdf

Reference66 articles.

1. Brown GC, Brown MM, Rapuano SB, Boyer D. Patient preference-based cost-utility analysis of VEGF-inhibitor therapy for neovascular age-related macular degeneration in the United States in 2018. Am J Ophthalmol. 2020;218:225–41. https://doi.org/10.1016/j.ajo.2020.05.029. (Epub 2020 Jun 19).

2. Maguire M.G., Martin D.F., Ying G., et al., for the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group Writing Committee. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration. The comparison of age-related macular treatments trials. Ophthalmology 2016; 123:1751–1761. doi: https://doi.org/10.1016/j.ophtha.2016.03.045. Epub 2016 May 2.

3. Ando R, Hirooka K, Saito M, et al. Two-year clinical outcomes of triple therapy with photodynamic therapy, anti-vascular endothelial growth factor agent, and triamcinolone acetonide for neovascular age-related macular degeneration. Jpn J Ophthalmol. 2023;67:50–8. https://doi.org/10.1007/s10384-022-00955-8. (Epub 2022 Nov 8).

4. Kovacs KD, Quirk MT, Kinoshita T, et al. A retrospective analysis of triple combination therapy with intravitreal bevacizumab, posterior sub-tenon's triamcinolone acetonide, and low-fluence verteporfin photodynamic therapy in patients with neovascular age-related macular degeneration. Retina. 2011; 31:446–52. doi: https://doi.org/10.1097/IAE.0b013e3181f6391f, http://www.ncbi.nlm.nih.gov/pubmed/21336068.

5. Olk RJ, Peralta E, Gierhart DL, et al. Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis. Int J Retin Vitr. 2015. https://doi.org/10.1186/s40942-015-0019-2. (eCollection 2015).